Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence : a network meta-analysis
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Takotsubo syndrome (TTS) is an acute heart failure syndrome, featured by transient left ventricular systolic dysfunction. Recurrences of TTS are not infrequent and there is no standard preventive therapy. The aim of this study was to evaluate in a network meta-analysis if beta-blockers (BB) and ACE inhibitors/angiotensin receptor blockers (ACEi/ARBs), in combination or not, can effectively prevent TTS recurrences.
METHODS: We performed a systematic network meta-analysis, using MEDLINE/EMBASE and the Cochrane Central Register of Controlled Trials for clinical studies published between January 2010 and September 2022. We considered all those studies including patients receiving medical therapy with BB, ACEi/ARBs. The primary outcome was TTS recurrence.
RESULTS: We identified 6 clinical studies encompassing a total of 3407 patients with TTS. At 40±10 months follow-up, TTS recurrence was reported in 160 (4.7%) out of 3407 patients. Mean age was 69.8±2 years and 394 patients (11.5%) out of 3407 were male. There were no differences in terms of TTS recurrence when comparing ACEi/ARBs versus control (OR 0.83; 95% CI 0.47 to 1.47, p=0.52); BB versus control (OR 1.01; 95% CI 0.63 to 1.61, p=0.96) and ACEi/ARBs versus BB (OR 0.88; 95% CI 0.51 to 1.53, p=0.65).Combination of BB and ACEi/ARBs was also not effective in reducing the risk of recurrence versus control (OR 0.91; 95% CI 0.58 to 1.43, p=0.68) vs ACEi/ARBs (OR 0.79; 95% CI 0.46 to 1.34, p=0.38)) and vs BB (OR 0.77; 95% CI 0.49 to 1.21, p=0.26).
CONCLUSIONS: Our study did not find sufficient statistical evidence regarding combination therapy with BB and ACEi/ARBs in reduction of TTS recurrence.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
---|---|
Enthalten in: |
Heart (British Cardiac Society) - 110(2024), 7 vom: 12. März, Seite 476-481 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Santoro, Francesco [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenergic beta-Antagonists |
---|
Anmerkungen: |
Date Completed 14.03.2024 Date Revised 24.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/heartjnl-2023-322980 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM361643519 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM361643519 | ||
003 | DE-627 | ||
005 | 20240324234803.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/heartjnl-2023-322980 |2 doi | |
028 | 5 | 2 | |a pubmed24n1344.xml |
035 | |a (DE-627)NLM361643519 | ||
035 | |a (NLM)37666647 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Santoro, Francesco |e verfasserin |4 aut | |
245 | 1 | 0 | |a Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence |b a network meta-analysis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.03.2024 | ||
500 | |a Date Revised 24.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a INTRODUCTION: Takotsubo syndrome (TTS) is an acute heart failure syndrome, featured by transient left ventricular systolic dysfunction. Recurrences of TTS are not infrequent and there is no standard preventive therapy. The aim of this study was to evaluate in a network meta-analysis if beta-blockers (BB) and ACE inhibitors/angiotensin receptor blockers (ACEi/ARBs), in combination or not, can effectively prevent TTS recurrences | ||
520 | |a METHODS: We performed a systematic network meta-analysis, using MEDLINE/EMBASE and the Cochrane Central Register of Controlled Trials for clinical studies published between January 2010 and September 2022. We considered all those studies including patients receiving medical therapy with BB, ACEi/ARBs. The primary outcome was TTS recurrence | ||
520 | |a RESULTS: We identified 6 clinical studies encompassing a total of 3407 patients with TTS. At 40±10 months follow-up, TTS recurrence was reported in 160 (4.7%) out of 3407 patients. Mean age was 69.8±2 years and 394 patients (11.5%) out of 3407 were male. There were no differences in terms of TTS recurrence when comparing ACEi/ARBs versus control (OR 0.83; 95% CI 0.47 to 1.47, p=0.52); BB versus control (OR 1.01; 95% CI 0.63 to 1.61, p=0.96) and ACEi/ARBs versus BB (OR 0.88; 95% CI 0.51 to 1.53, p=0.65).Combination of BB and ACEi/ARBs was also not effective in reducing the risk of recurrence versus control (OR 0.91; 95% CI 0.58 to 1.43, p=0.68) vs ACEi/ARBs (OR 0.79; 95% CI 0.46 to 1.34, p=0.38)) and vs BB (OR 0.77; 95% CI 0.49 to 1.21, p=0.26) | ||
520 | |a CONCLUSIONS: Our study did not find sufficient statistical evidence regarding combination therapy with BB and ACEi/ARBs in reduction of TTS recurrence | ||
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Journal Article | |
650 | 4 | |a cardiomyopathies | |
650 | 4 | |a meta-analysis | |
650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
650 | 7 | |a Antihypertensive Agents |2 NLM | |
650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
700 | 1 | |a Sharkey, Scott |e verfasserin |4 aut | |
700 | 1 | |a Citro, Rodolfo |e verfasserin |4 aut | |
700 | 1 | |a Miura, Tetsuji |e verfasserin |4 aut | |
700 | 1 | |a Arcari, Luca |e verfasserin |4 aut | |
700 | 1 | |a Urbano-Moral, Jose Angel |e verfasserin |4 aut | |
700 | 1 | |a Stiermaier, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Nuñez-Gil, Ivan Javier |e verfasserin |4 aut | |
700 | 1 | |a Silverio, Angelo |e verfasserin |4 aut | |
700 | 1 | |a Di Nunno, Nicola |e verfasserin |4 aut | |
700 | 1 | |a Ragnatela, Ilaria |e verfasserin |4 aut | |
700 | 1 | |a Cetera, Rosa |e verfasserin |4 aut | |
700 | 1 | |a Nishida, Junichi |e verfasserin |4 aut | |
700 | 1 | |a Eitel, Ingo |e verfasserin |4 aut | |
700 | 1 | |a Brunetti, Natale Daniele |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Heart (British Cardiac Society) |d 1996 |g 110(2024), 7 vom: 12. März, Seite 476-481 |w (DE-627)NLM085989274 |x 1468-201X |7 nnns |
773 | 1 | 8 | |g volume:110 |g year:2024 |g number:7 |g day:12 |g month:03 |g pages:476-481 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/heartjnl-2023-322980 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 110 |j 2024 |e 7 |b 12 |c 03 |h 476-481 |